docetaxel anhydrous has been researched along with Neuroendocrine Tumors in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Aziz, T; Chow, MJ; Cutz, JC; Jayasekera, D; Kapoor, A; Major, P; Tang, D; Wei, F; Wong, N; Yan, J; Zheng, M | 1 |
| Endo, M; Igawa, S; Ito, I; Kaira, K; Kameya, T; Murakami, H; Naito, T; Nakamura, Y; Takahashi, T; Tsuya, A; Watanabe, R; Yamamoto, N | 1 |
2 other study(ies) available for docetaxel anhydrous and Neuroendocrine Tumors
| Article | Year |
|---|---|
Amplification of MUC1 in prostate cancer metastasis and CRPC development.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Animals; Antineoplastic Agents, Phytogenic; Biomarkers, Tumor; Cell Line, Tumor; Cell Movement; Computational Biology; Databases, Genetic; Disease Progression; Disease-Free Survival; Docetaxel; Gene Amplification; Gene Dosage; Gene Expression Regulation, Neoplastic; Gene Regulatory Networks; Humans; Male; Mice, Inbred NOD; Mice, SCID; Middle Aged; Mucin-1; Neoplastic Stem Cells; Neuroendocrine Tumors; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Receptors, Androgen; RNA, Messenger; Signal Transduction; Survival Analysis; Taxoids; Time Factors; Up-Regulation; Xenograft Model Antitumor Assays | 2016 |
Comparison of chemotherapy for unresectable pulmonary high-grade non-small cell neuroendocrine carcinoma and small-cell lung cancer.
Topics: Aged; Aged, 80 and over; Camptothecin; Carcinoma, Non-Small-Cell Lung; Disease Progression; Docetaxel; Drug Therapy, Combination; Female; Humans; Immunohistochemistry; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Neuroendocrine Tumors; Platinum Compounds; Survival Analysis; Taxoids; Vinblastine; Vinorelbine | 2010 |